Mirati Therapeutics Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2013)
Status: Acquired by Bristol-Myers Squibb (2023)

Organization Overview

First Clinical Trial
2013
NCT00323934
First Marketed Drug
2022
adagrasib (Krazati)
First NDA Approval
2022
adagrasib (Krazati)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Mirati Therapeutics | Mirati Therapeutics Inc. | MIRATI THERAPS